Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies

Tahmina Nasrin Poly, Md Mohaimenul Islam, Bruno Andreas Walther, Hsuan Chia Yang, Chieh Chen Wu, Ming Chin Lin, Yu Chuan Li

Research output: Contribution to journalArticle

Abstract

Background and Aims: The impact of statin on dementia risk reduction has been a subject of debate over the last decade, but the evidence remains inconclusive. Therefore, we performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between statin therapy and the risk of dementia. Methods: We systematically searched for relevant studies published from January 2000 to March 2018 using EMBASE, Google, Google Scholar, PubMed, Scopus, and Web of Science. Two authors performed study selection, data abstraction, and risk of bias assessment. We then extracted data from the selected studies and performed meta-analysis of observational studies using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: A total of 30 observational studies, including 9,162,509 participants (84,101 dementia patients), met the eligibility criteria. Patients with statin had a lower all-caused dementia risk than those without statin (risk ratio [RR] 0.83, 95% CI 0.79-0.87, I2 = 57.73%). The overall pooled reduction of Alzheimer disease in patients with statin use was RR 0.69 (95% CI 0.60-0.80, p < 0.0001), and the overall pooled RR of statin use and vascular dementia risk was RR 0.93 (95% CI 0.74-1.16, p = 0.54). Conclusion: This study suggests that the use of statin is significantly associated with a decreased risk of dementia. Future studies measuring such outcomes would provide useful information to patients, clinicians, and policymakers. Until further evidence is established, clinicians need to make sure that statin use should remain restricted to the treatment of cardiovascular disease.

Original languageEnglish
JournalNeuroepidemiology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Observational Studies
Dementia
Meta-Analysis
Odds Ratio
Vascular Dementia
Risk Reduction Behavior
PubMed
Alzheimer Disease
Cardiovascular Diseases
Therapeutics

Keywords

  • Alzheimer
  • Cardiac disease
  • Dementia
  • Meta-analysis
  • Statin
  • Vascular dementia

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Association between Use of Statin and Risk of Dementia : A Meta-Analysis of Observational Studies. / Poly, Tahmina Nasrin; Islam, Md Mohaimenul; Walther, Bruno Andreas; Yang, Hsuan Chia; Wu, Chieh Chen; Lin, Ming Chin; Li, Yu Chuan.

In: Neuroepidemiology, 01.01.2019.

Research output: Contribution to journalArticle

@article{c1a38dde92f344f89fa3c95f2109803e,
title = "Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies",
abstract = "Background and Aims: The impact of statin on dementia risk reduction has been a subject of debate over the last decade, but the evidence remains inconclusive. Therefore, we performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between statin therapy and the risk of dementia. Methods: We systematically searched for relevant studies published from January 2000 to March 2018 using EMBASE, Google, Google Scholar, PubMed, Scopus, and Web of Science. Two authors performed study selection, data abstraction, and risk of bias assessment. We then extracted data from the selected studies and performed meta-analysis of observational studies using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: A total of 30 observational studies, including 9,162,509 participants (84,101 dementia patients), met the eligibility criteria. Patients with statin had a lower all-caused dementia risk than those without statin (risk ratio [RR] 0.83, 95{\%} CI 0.79-0.87, I2 = 57.73{\%}). The overall pooled reduction of Alzheimer disease in patients with statin use was RR 0.69 (95{\%} CI 0.60-0.80, p < 0.0001), and the overall pooled RR of statin use and vascular dementia risk was RR 0.93 (95{\%} CI 0.74-1.16, p = 0.54). Conclusion: This study suggests that the use of statin is significantly associated with a decreased risk of dementia. Future studies measuring such outcomes would provide useful information to patients, clinicians, and policymakers. Until further evidence is established, clinicians need to make sure that statin use should remain restricted to the treatment of cardiovascular disease.",
keywords = "Alzheimer, Cardiac disease, Dementia, Meta-analysis, Statin, Vascular dementia",
author = "Poly, {Tahmina Nasrin} and Islam, {Md Mohaimenul} and Walther, {Bruno Andreas} and Yang, {Hsuan Chia} and Wu, {Chieh Chen} and Lin, {Ming Chin} and Li, {Yu Chuan}",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000503105",
language = "English",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Association between Use of Statin and Risk of Dementia

T2 - A Meta-Analysis of Observational Studies

AU - Poly, Tahmina Nasrin

AU - Islam, Md Mohaimenul

AU - Walther, Bruno Andreas

AU - Yang, Hsuan Chia

AU - Wu, Chieh Chen

AU - Lin, Ming Chin

AU - Li, Yu Chuan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Aims: The impact of statin on dementia risk reduction has been a subject of debate over the last decade, but the evidence remains inconclusive. Therefore, we performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between statin therapy and the risk of dementia. Methods: We systematically searched for relevant studies published from January 2000 to March 2018 using EMBASE, Google, Google Scholar, PubMed, Scopus, and Web of Science. Two authors performed study selection, data abstraction, and risk of bias assessment. We then extracted data from the selected studies and performed meta-analysis of observational studies using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: A total of 30 observational studies, including 9,162,509 participants (84,101 dementia patients), met the eligibility criteria. Patients with statin had a lower all-caused dementia risk than those without statin (risk ratio [RR] 0.83, 95% CI 0.79-0.87, I2 = 57.73%). The overall pooled reduction of Alzheimer disease in patients with statin use was RR 0.69 (95% CI 0.60-0.80, p < 0.0001), and the overall pooled RR of statin use and vascular dementia risk was RR 0.93 (95% CI 0.74-1.16, p = 0.54). Conclusion: This study suggests that the use of statin is significantly associated with a decreased risk of dementia. Future studies measuring such outcomes would provide useful information to patients, clinicians, and policymakers. Until further evidence is established, clinicians need to make sure that statin use should remain restricted to the treatment of cardiovascular disease.

AB - Background and Aims: The impact of statin on dementia risk reduction has been a subject of debate over the last decade, but the evidence remains inconclusive. Therefore, we performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between statin therapy and the risk of dementia. Methods: We systematically searched for relevant studies published from January 2000 to March 2018 using EMBASE, Google, Google Scholar, PubMed, Scopus, and Web of Science. Two authors performed study selection, data abstraction, and risk of bias assessment. We then extracted data from the selected studies and performed meta-analysis of observational studies using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: A total of 30 observational studies, including 9,162,509 participants (84,101 dementia patients), met the eligibility criteria. Patients with statin had a lower all-caused dementia risk than those without statin (risk ratio [RR] 0.83, 95% CI 0.79-0.87, I2 = 57.73%). The overall pooled reduction of Alzheimer disease in patients with statin use was RR 0.69 (95% CI 0.60-0.80, p < 0.0001), and the overall pooled RR of statin use and vascular dementia risk was RR 0.93 (95% CI 0.74-1.16, p = 0.54). Conclusion: This study suggests that the use of statin is significantly associated with a decreased risk of dementia. Future studies measuring such outcomes would provide useful information to patients, clinicians, and policymakers. Until further evidence is established, clinicians need to make sure that statin use should remain restricted to the treatment of cardiovascular disease.

KW - Alzheimer

KW - Cardiac disease

KW - Dementia

KW - Meta-analysis

KW - Statin

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=85073192403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073192403&partnerID=8YFLogxK

U2 - 10.1159/000503105

DO - 10.1159/000503105

M3 - Article

C2 - 31574510

AN - SCOPUS:85073192403

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

ER -